Unicontin - E - 400

Quick links to important sections

Unicontin - E - 400

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unicontin - E - 400

Quick Facts: Unicontin-E 400

Property Description
Active ingredient Theophylline
Form Controlled-release tablet (CR)
Pharmacological class Bronchodilator
Common use Maintenance for chronic respiratory issues
Origin Synthetic xanthine derivative

Unicontin-E 400: Identity and Pharmacological Class

Unicontin-E 400 is a prescription-only pharmaceutical preparation primarily classified as a bronchodilator medication, which is used for the maintenance management of chronic respiratory conditions. This drug entity’s core identity is defined by its function: facilitating easier airflow within the respiratory tract over extended periods. It is utilized as a foundational, long-term approach to help sustain open air passages, a function clinically recognized for managing persistent respiratory difficulties.

The medication belongs to a specific type of respiratory medication whose mechanism focuses on causing smooth muscle relaxation in the lungs. The classification of theophylline as a bronchodilator is widely recognized by major authoritative bodies, helping support continuous therapeutic use.


Composition and Theophylline's Chemical Origin

The active ingredient in Unicontin-E 400 is Theophylline, which is a synthetic xanthine derivative, or methylxanthine, responsible for the drug's therapeutic effects. This single-ingredient product is defined by the chemical nature of theophylline. Research confirms that theophylline is structurally related to xanthine compounds found in nature but is formulated specifically for its potent action on the airways.

Theophylline achieves its physiological action by widening the air passages through the relaxation of the bronchial muscles. Its composition as a xanthine derivative is directly linked to its function, providing the essential bronchodilator effect for supporting respiratory function.


Why is Unicontin-E 400 a Controlled-Release Tablet?

Unicontin-E 400 is manufactured as a controlled-release tablet (CR), a specialized dosage form designed to ensure the active ingredient is released slowly and continuously after oral route of administration. This formulation differs significantly from standard, immediate-release tablets because the Theophylline is contained within a solid pharmaceutical excipient matrix that regulates absorption.

The general therapeutic purpose of utilizing the controlled-release design is to provide sustained relief and maintain consistent, therapeutic levels of theophylline in the body throughout the day and night. This prolonged effect is crucial for maintenance therapy, which is a key advantage specifically highlighted in long-term treatment strategies.

Regulatory References

  1. NIH: Theophylline (Bronchodilator)

What side effects are possible with Unicontin - E - 400?

Possible Side Effects and Safety Information

Theophylline, the active ingredient in Unicontin-E 400, has an officially documented safety profile characterized by system-organ-class effects and a strong relationship between blood concentration and the severity of adverse reactions.


Documented Adverse Reactions by System

Adverse reactions are frequently reported across several physiological systems. Common reactions often involve the Gastrointestinal System (e.g., nausea, vomiting, epigastric pain) and the Central Nervous System (e.g., headache, tremors, insomnia, irritability). Cardiovascular effects, such as tachycardia (rapid heart rate) and palpitations, are also officially listed in regulatory documents.


Serious Reactions and Safety Constraints

Regulatory documents emphasize that the frequency and severity of adverse effects increase substantially when the drug's serum concentration exceeds a threshold of 20 mu g/mL. At these elevated levels, there is an official, documented risk of serious adverse reactions, including generalized seizures (convulsions) and potentially life-threatening ventricular arrhythmias.

Safety restrictions require caution in patients with specific pre-existing conditions. These include cardiac arrhythmias, peptic ulcer disease, and seizure disorders. Furthermore, the official profile notes that conditions like hepatic impairment (liver disease), congestive heart failure, and advanced age (over 60 years) can significantly reduce the body's clearance of theophylline, officially increasing the risk of drug accumulation and toxicity.

Overdose and Emergency Response

Overdose and when to seek help

This information is strictly derived from official government regulatory sources and addresses the documented manifestations of Theophylline overdose and the required emergency actions.

Overdose Scope

Domain Official Regulatory Statements
Documented overdose presentations Initial manifestations may include nausea, persistent vomiting, headache, agitation, and tremor. Severe overdose may lead to gastrointestinal bleeding and metabolic abnormalities like hypokalaemia and hyperglycaemia.
Physiological systems affected Overdose primarily affects the Central Nervous System (CNS), Cardiovascular system, and Gastrointestinal tract. Severe CNS effects include seizures; severe cardiovascular effects include major cardiac arrhythmias.
Population-specific overdose notes Regulatory documents note that children are particularly susceptible to the severe manifestation of seizures. The elderly and patients with underlying cardiac or hepatic disease are at increased risk of toxicity and complications.
When immediate medical help is required Seek immediate medical attention for any suspected overdose or when symptoms of severe toxicity, such as seizures, persistent vomiting, or severe cardiac palpitations, are present.

Overdose Classifications (High-Level)

Classification Official Regulatory Wording / Description
Severity classification Defined by clinical effects ranging from mild toxicity to life-threatening toxicity, encompassing events like cardiovascular collapse and refractory seizures.
Overdose-context constraints There is no specific antidote known; management involves symptomatic and supportive treatment, including the immediate use of activated charcoal and measures to enhance drug clearance.

Connection to the Overall Overdose Profile

Official documents define the Theophylline overdose profile by enumerating the progression from common symptoms to potentially fatal outcomes. This profile mandates specific instructions to seek immediate medical attention for any suspected exposure and requires continuous cardiac monitoring and frequent serum theophylline concentration testing while under hospital observation.

Therapeutic Uses of Unicontin - E - 400

What Unicontin-E 400 Treats: Main Uses and Benefits

Unicontin-E 400 is commonly used as a foundational maintenance treatment for chronic obstructive lung diseases, specifically bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD). The treatment addresses the long-term patterns of recurring symptoms, such as persistent wheezing and chest tightness. The medication may assist in easing the physiological strain associated with persistent airflow constriction. This supportive management is relevant for easing recurring shortness of breath (dyspnea), which can be disruptive during daily activities or when symptoms become more noticeable at night, and may contribute to improved functional comfort.

The clinical applications are relevant for the long-term management of conditions like chronic asthma, chronic bronchitis, and emphysema. It is often applied when symptoms create noticeable physiological strain despite other primary management options. Its use may provide supportive symptomatic relief.

“This medication is applied across domains where additional symptomatic support is needed to address symptoms that interfere with daily comfort.”


Quick Fact: Relief for Persistent Airflow Symptoms

Feature Description
Therapeutic Use Focus Maintenance management of Asthma and COPD
Symptom Focus Persistent Wheezing and Shortness of Breath
Context of Use Adjunctive therapy for chronic symptoms of heightened physiological activity
Supportive Role Supports the easing of overall symptom load and functional stability

Regulatory References

  1. DailyMed FDA Labeling for Theophylline

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Unicontin - E - 400 — Official Regulatory Information


Eligibility Scope

Classification Status and Context
Populations for whom use is allowed Adults and adolescents aged 12 years and older for maintenance therapy.
Populations for whom use is not recommended Children under 12 years, as safety and effectiveness are not fully established.
Populations for whom use is contraindicated Individuals with known hypersensitivity to theophylline or xanthine derivatives, and infants under six months of age. Contraindications also apply to patients with porphyria or active peptic ulcers.
Age-related eligibility rules Infants under six months are formally contraindicated. Older adults (ge 60 years) require special caution due to an increased risk of reduced clearance.
Condition-specific eligibility rules Patients with impaired hepatic function (liver disease), severe cardiac conditions (e.g., congestive heart failure), or seizure disorders require conditional use only with close monitoring, as these increase toxicity risk.
Pregnancy and lactation eligibility status Pregnancy Category C. Use during pregnancy is only recommended if the benefit justifies the potential risk. The drug is excreted into breast milk, requiring caution during lactation.

Eligibility Classifications (High-Level)

Classification Type Examples as defined in Official Documents
Eligibility severity classification Contraindicated; Not Established; Caution/Restricted Use.
Regulatory basis Official prescribing information (SmPC, FDA Prescribing Information).
Eligibility-context constraints Constraints are primarily tied to physiological clearance capacity (hepatic/cardiac function) and age-related risk.

Resulting Eligibility Structure

Official eligibility statements:

  • Contraindicated in patients with a known hypersensitivity to xanthines and in infants under 6 months of age.
  • Safety and effectiveness have not been established in children under 12 years of age.
  • Use requires extreme caution in patients with impaired liver function or severe cardiac disease due to the risk of toxicity.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use this medicine by establishing formal contraindications for specific patient groups and mandatory caution for populations where drug metabolism is highly variable or slowed (e.g., older adults, hepatic impairment). This structured approach ensures patient selection aligns with the drug's narrow therapeutic index profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents establish three main classifications for interactions involving Theophylline (the active ingredient in Unicontin-E 400): contraindicated combinations, exposure-modifying metabolic effects, and pharmacodynamic potentiation. This information is critical for understanding co-administration restrictions.


Documented Interaction Classifications

Classification Interacting Agents / Examples
Formal Contraindications Riociguat, Viloxazine, and Ephedrine (in specific pediatric age/weight groups) are officially listed as prohibited for concurrent use.
Reduced Clearance / Increased Exposure Ciprofloxacin, Erythromycin (macrolide antibiotics), and Cimetidine are documented to reduce Theophylline's metabolic clearance, leading to elevated plasma concentrations.
Increased Clearance / Reduced Exposure Rifampicin, Phenytoin, and Carbamazepine are documented to increase Theophylline clearance, resulting in lower plasma concentrations.
Pharmacodynamic Potentiation Concurrent use with Beta-adrenergic agonists or other Xanthine drugs may result in additive physiological effects.

Non-Medicinal Substance and Population Notes

Non-medicinal substances, including tobacco and cannabis smoking, and the herbal product St. John's Wort, are officially documented to increase Theophylline's clearance. This can affect exposure. Furthermore, regulatory information notes that clearance is substantially reduced in patients with hepatic impairment and in elderly patients, which elevates the risk associated with all exposure-modifying interactions.

Mechanism of Action

Unicontin-E 400 contains the active substance theophylline, a methylxanthine derivative. Its pharmacodynamic action is exerted through multiple pathways at the cellular level to modulate overactive physiological processes.

Modulation of Cyclic Nucleotides

This primary domain involves the non-selective inhibition of phosphodiesterase (PDE) enzymes, particularly PDE3 and PDE4. By blocking the enzymatic hydrolysis of cyclic adenosine monophosphate (cAMP), theophylline elevates the intracellular concentration of cAMP. This increase modifies calcium signaling and kinase activity within smooth muscle cells, influencing smooth muscle cell contractility.

Adenosine Receptor Antagonism

Theophylline also acts as a competitive antagonist at adenosine receptors, including A1, A2A, and A2B subtypes. Adenosine signaling is implicated in the release of various cellular mediators. This antagonism results in the attenuation of adenosine-mediated signaling cascades.

Influence on Gene Expression

A distinct mechanism involves the drug’s ability to increase the activity of histone deacetylase 2 (HDAC2), independent of PDE inhibition. This molecular process modulates transcription factor activity, leading to altered expression of specific pro-inflammatory gene products within targeted cells.

Dosage and Administration Information

Unicontin-E 400 is an oral medication administered as a controlled-release tablet and is intended exclusively for long-term maintenance therapy. The tablet must be swallowed whole and must not be crushed, cut, or chewed to ensure the controlled release of the active ingredient, Theophylline. The standard adult starting dose typically ranges from 300 mg to 400 mg per day, administered either once daily or in divided doses, with the maintenance dosage guided by clinical factors and monitoring.

To maintain stable concentrations of the active ingredient, the medicine must be taken at the same time every day and its intake must be consistent with respect to meals (always with food or always without). The usual maintenance dosage is between 400 mg and 600 mg per day, though the final dose is titrated based on periodic measurement of Theophylline serum concentration. Any dose adjustment, up or down, is conducted cautiously at intervals of no less than three days to allow the new dosage to achieve a steady-state level.

Specific instructions are included for certain populations. The total daily dose for older adults (over 60 years) is often capped and generally should not exceed 400 mg. Furthermore, patients with hepatic impairment require a specific modification to their dosage due to altered drug clearance. If a dose is missed, it is advised to skip the forgotten dose and take the next dose at the regularly scheduled time; a double dose must not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Unicontin-E 400


Evidence for Maintenance Use in Chronic Obstructive Pulmonary Disease (COPD)

Research examining the drug entity Unicontin-E 400 (Theophylline) for stable, long-term management of COPD includes Randomized Controlled Trials (RCTs) and Systematic Reviews. These investigations were primarily used in research exploring how symptoms change over time in adults characterized by conditions marked by functional limitations, such as moderate to severe COPD. Researchers examined objective lung function parameters like FEV1 and FVC, as well as patient-reported measures of health status.

Research describing patterns related to exacerbation rates was mixed across different large-scale studies. In addition, large observational cohort studies have data show patterns related to all-cause mortality, but the findings in this area have presented conflicting patterns in the scientific literature. Research exploring the drug entity includes numerous RCTs, but the findings across those studies show variability. Limited information for long-term outcomes remains a key concern because of the inconsistency in observational data. Furthermore, comparative evidence is lacking to fully establish the drug entity's role against the newest standard-of-care treatments for COPD currently available.


Evidence for Maintenance Use in Bronchial Asthma

Theophylline was evaluated in research for the long-term management of chronic asthma, mainly when used as an add-on therapy alongside inhaled medications. Studies often utilized RCTs and Systematic Reviews to explore short-term symptom changes in adults and children/adolescents with asthma. Studies monitored objective functional measures like Peak Expiratory Flow Rate (PEFR) and FEV1. Findings describe patterns observed in the studies, including measurements of functional changes in lung parameters.

Research exploring the drug entity includes numerous RCTs; however, contemporary evidence highlights a limited number of recent, large-scale RCTs directly comparing it to all current first-line standard therapies for maintenance, meaning the certainty remains low regarding the research context for its current use.


Research Gaps and Areas of Scientific Uncertainty

Despite a long history of research, there are several areas where the evidence quality varies across studies and where certainty remains low. The evidence examined patterns related to long-term mortality, primarily evaluated in observational studies, has produced mixed findings; data for this long-term outcome are not consistently reported. This research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.

Key Studies & References

  1. DailyMed Labeling for Theophylline Extended-Release Tablets (Theophylline)

Frequently Asked Questions (FAQ)

Common questions about Unicontin - E - 400 (FAQ)


Q: What happens if I miss a scheduled dose of Unicontin - E - 400?

If a dose is missed, official instructions state to skip the forgotten dose and take the next one at the regularly scheduled time. Official instructions advise that a double dose must not be taken to compensate. This warning is in place because the severity of adverse effects, such as seizures and irregular heart rhythms, is documented to increase substantially if the level of the active ingredient in the blood exceeds a safe threshold.


Q: How does the extended-release feature of Unicontin - E - 400 benefit the user?

The extended-release design is specialized to release the active ingredient slowly and continuously over a long period. This formulation helps to maintain consistent therapeutic levels of the medicine in your body throughout the day. This sustained action is crucial for the long-term management and maintenance of chronic respiratory issues.


Q: Can Unicontin - E - 400 be used during pregnancy or while breastfeeding?

According to official product information, this medicine is categorized as Pregnancy Category C. This classification indicates that the potential benefits may be determined to warrant use despite potential risks, as adequate human studies are not available. The active ingredient is documented to be excreted into breast milk, and official information notes the potential for irritability or other mild toxicities in the nursing infant.


Q: Is it normal to feel a bit shaky or nervous after taking this medication?

The official safety profile lists tremors (shaking) and nervousness among the common side effects associated with the active ingredient. Adverse reactions may be more noticeable when beginning therapy or after a dosage change.


Q: Can I take Unicontin - E - 400 if I have a heart condition?

Official documents state that individuals with certain heart conditions, such as cardiac arrhythmias or severe cardiac conditions, require special caution and close monitoring. The active ingredient is known to cause cardiovascular effects, including a rapid or irregular heartbeat, which is a documented risk.


Q: Is Unicontin - E - 400 used for breathing problems only?

Official regulatory documents indicate that the medicine is primarily used for the long-term maintenance (management) of chronic respiratory conditions. This includes conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD), which affect breathing and lung function.


Q: How quickly should someone expect to feel the effect of Unicontin - E - 400?

Unicontin - E - 400 is designed for maintenance, not for immediate relief. Official product information states that it does not work right away and should not be used to relieve sudden breathing problems. Peak levels in the bloodstream are generally achieved several hours after taking a dose.


Q: Why does Unicontin - E - 400 have 'E - 400' in the name?

The name Unicontin - E - 400 is the proprietary brand name for the medicine. The '400' designation typically refers to the 400 mg strength of the active ingredient in the tablet. The 'E' often signifies the Extended-Release formulation.


Q: Can Unicontin - E - 400 cause problems with sleep?

Yes, regulatory labeling lists insomnia and trouble sleeping as commonly reported side effects. These effects are related to the active ingredient's chemical properties.


Q: Is it true that Unicontin - E - 400 needs to be taken on an empty stomach?

Official regulatory instructions emphasize that the medicine must be taken at the same time every day, and its intake must be consistent with respect to meals—always with food or always without food. This consistency is critical for maintaining stable levels in the bloodstream. The necessity of taking it either with or without food is addressed in the product instructions for the specific formulation.


Q: What are the common side effects people report when taking Unicontin - E - 400?

Commonly documented adverse reactions often involve the Central Nervous System and the Gastrointestinal System. These include nausea, vomiting, stomach pain, headache, tremors, irritability, and insomnia. The frequency and severity of these reactions are documented to increase substantially at higher blood concentrations.


Q: Is a slight headache a normal expectation when starting Unicontin - E - 400?

Headache is officially listed as a common adverse reaction associated with the use of the active ingredient. Adverse reactions may be more pronounced when beginning therapy or after any adjustment to the dosage.


Q: Can Unicontin - E - 400 be taken with common pain relievers like ibuprofen?

Official regulatory documents do not list a specific clearance-changing interaction between the active ingredient and ibuprofen. However, official information notes the risks associated with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which requires careful consideration.


Q: How is Unicontin - E - 400 different from a short-acting version of the same drug?

Unicontin - E - 400 is a controlled-release formulation, designed for long-term maintenance by releasing the active ingredient slowly over many hours. A short-acting (immediate-release) version is absorbed much faster, providing a quicker peak level and shorter overall duration of effect.


Q: Is Unicontin - E - 400 a controlled substance?

No, the active ingredient, Theophylline, is classified as a prescription-only medicine by major authoritative bodies. It is not scheduled as a federally controlled substance in countries like the United States, United Kingdom, or Australia.


Q: Are there any specific supplements or vitamins to avoid while on Unicontin - E - 400?

Official documents note that some herbal products, such as St. John's Wort, can alter the clearance of the active ingredient, leading to lower concentrations. Official guidance suggests that patients should report all medications, vitamins, and herbal products to a healthcare provider.


Q: Does Unicontin - E - 400 affect blood pressure?

Yes, the official safety profile notes that the active ingredient may be associated with hypotension (low blood pressure) as an adverse effect. High or low blood pressure is also a documented symptom of overdose.


Q: Are there any known interactions between Unicontin - E - 400 and alcohol?

Official drug interaction documentation notes that a single large dose of alcohol can decrease the clearance of the active ingredient. This increases the concentration in the bloodstream and elevates the risk of experiencing side effects.


Q: What are the signs that Unicontin - E - 400 might be causing a serious issue?

Signs of a serious issue or toxicity are documented to occur when the drug concentration is too high. These can include severe symptoms like generalized seizures (convulsions), persistent or uncontrollable vomiting, and significant irregular heart rhythms.


Q: Does Unicontin - E - 400 interact with birth control pills?

Yes, official drug interaction tables state that oral contraceptives containing estrogen can decrease the body's clearance of the active ingredient. This potential for higher concentrations means close monitoring may be required.


Q: How long does the effect of one Unicontin - E - 400 tablet last?

Because it is a controlled-release formulation, the tablet is designed to provide sustained effects over an extended period. Official regulatory information indicates the product allows for a 12-hour dosing interval for most patients, and in selected cases, may be extended to a 24-hour dosing interval.


Q: Is it safe to drive or operate machinery after taking Unicontin - E - 400?

Official documents list common side effects that can potentially affect attention, such as dizziness and tremors. Patients should be aware of how the medicine affects them before attempting to drive or operate machinery.


Q: Is Unicontin - E - 400 known to interact with caffeine?

Yes, official drug information documents state that caffeine is pharmacologically similar to the active ingredient and can increase the frequency of side effects. These include the intensification of adverse reactions such as nausea, tremors, and insomnia.


Q: Has there been much research on the long-term effects of Unicontin - E - 400?

Research examining the active ingredient for long-term management includes a long history of studies, such as Randomized Controlled Trials (RCTs) and systematic reviews. However, official regulatory overviews note that the evidence quality varies and that certainty remains low regarding some long-term outcomes, such as mortality data.


Q: Can Unicontin - E - 400 be stopped suddenly?

It is not generally recommended to stop the medicine abruptly, especially after long-term use. Regulatory guidance suggests that abrupt discontinuation may lead to a worsening of underlying respiratory symptoms.


Q: Is Unicontin - E - 400 used for cough or congestion?

The main indications are the long-term management of chronic conditions like asthma and COPD. While some research has examined its use to help control chronic cough in stable patients with asthma, it is not intended for the acute relief of general cough or congestion.


Q: Can Unicontin - E - 400 cause digestive issues like nausea or stomach upset?

Yes, the official safety profile documents that the most frequently reported adverse reactions involve the Gastrointestinal System. These commonly include nausea, vomiting, and epigastric (stomach) pain.


Q: Is it described in official sources that Unicontin - E - 400 interacts with herbal remedies?

Yes, official documentation specifically names the herbal product St. John's Wort as one that is documented to increase the body's clearance of the active ingredient. This can reduce the medicine's effectiveness. Official guidance suggests that patients should report all medications, vitamins, and herbal products to a healthcare provider.


Q: Do studies suggest that certain foods interfere with the absorption of the medicine?

Official regulatory documents note that certain major dietary changes, such as shifts between high protein/low carbohydrate and high carbohydrate/low protein diets, can alter the clearance of the active ingredient. Additionally, the consumption of charcoal-broiled beef is documented to increase clearance.


Q: What kind of warnings are included in the packaging for Unicontin - E - 400?

Key warnings in official documentation focus on the risk of serious adverse reactions (like seizures and irregular heart rhythms) if blood concentrations exceed the therapeutic range. Caution is strictly mandated for specific patient groups, including those with hepatic impairment (liver disease), cardiac arrhythmias, and seizure disorders.


Q: Is it possible to be allergic to Unicontin - E - 400?

Yes, regulatory documents list a known hypersensitivity (allergic reaction) to theophylline or other xanthine derivatives as a formal contraindication. Signs of a serious allergic reaction, such as rash or swelling, are documented.


Q: Does Unicontin - E - 400 cause any specific mood changes?

Official documents list irritability as a common adverse reaction. More severe mental or mood changes, such as agitation or confusion, are documented as potential symptoms of overdose or toxicity.


Q: Are there specific laboratory tests recommended before starting this medication?

Official guidelines recommend that the Theophylline serum concentration should be measured when initiating therapy. This laboratory test is typically conducted to help guide the dosage adjustment and ensure the patient is within the intended therapeutic range.


Q: What happens if I take more than the recommended amount of Unicontin - E - 400?

Taking more than the recommended amount can lead to toxicity (overdose). Symptoms documented in regulatory information include severe gastrointestinal issues like persistent vomiting, as well as life-threatening events such as generalized seizures (convulsions) and irregular heart rhythms.

How should Unicontin - E - 400 be stored and disposed of?

How to Store and Dispose of Unicontin-E 400

The storage and disposal of Unicontin-E 400 (Theophylline prolonged-release tablets) must strictly adhere to the conditions mandated by regulatory labeling to ensure product stability and safety.

Official Storage and Handling

Requirement Details from Regulatory Labels
Temperature Store below 30 C (at controlled room temperature).
Protection Keep away from excess heat, light, and moisture.
Container Rule Must be kept in the original container and be tightly closed.
Child Safety Mandatorily keep out of the sight and reach of children at all times.

Disposal Requirements

Unused or expired medication must be discarded before its expiry date. The official instruction requires following local waste regulations for the proper disposal of pharmaceuticals. No specialized handling for hazardous waste is typically documented for this product. These constraints are essential for maintaining the product's quality and ensuring household safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Unicontin - E - 400 found in:

A-Z Index: